Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

iNK Cell–Driven Strategies for Enhanced Multiple Myeloma ImmunotherapY

Obiettivo

"Despite the transformative potential of CAR-T cell therapies, their widespread adoption is hindered by significant barriers, including prohibitive costs, severe toxicities, logistical challenges in manufacturing, and limited efficacy. The iN-KEY consortium aims to overcome these challenges by developing and clinically validating a next-generation, ""off-the-shelf"" immunotherapy platform for the treatment of Multiple Myeloma (MM). At the heart of this project is a disruptive platform based on engineered induced Pluripotent Stem Cells (iPSCs). This platform integrates several key innovations: 1) Highly immunocompatible, haplo-matched iPSC lines for broad allogeneic use; 2) A proprietary, high-capacity Docking Platform (DoP) for safe, precise, and multiplexed integration of effector genes, eliminating the risks associated with viral vectors; 3) A dual-targeting strategy combining a Chimeric Antigen Receptor (CAR) against BCMA and a Synthetic T-cell Activating Bifunctional (STAb) construct against CD19; and 4) A suite of additional effector genes to enhance cell persistence, homing, and safety. This therapeutic product will be manufactured using a scalable, automated, and feeder-free GMP process, with quality control enhanced by novel multi-omics and AI-driven methodologies to ensure product consistency and safety. The project will culminate in a first-in-human clinical trial to assess the safety and preliminary efficacy of the therapy in patients with relapsed/refractory Multiple Myeloma. By addressing the core challenges of scalability, safety, accessibility, and cost, the iN-KEY platform has the potential to unlock a new generation of complex, affordable, and highly effective immunotherapies, benefiting patients and healthcare systems across Europe and beyond."

Campo scientifico (EuroSciVoc)

Questo progetto non è ancora stato classificato con EuroSciVoc.
Suggerisci i campi scientifici che ritieni più rilevanti e aiutaci a migliorare il nostro servizio di classificazione.

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-RIA - HORIZON Research and Innovation Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-HLTH-2025-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

BANC DE SANG I TEIXITS
Contributo netto dell'UE
€ 2 475 046,25
Indirizzo
PASSEIG TAULAT 106-116
08005 Barcelona
Spagna
Regione
Este Cataluña Barcelona
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 2 475 046,25

Partecipanti (12)